These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9302142)

  • 21. Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients.
    Cozzarini C; Bolognesi A; Ceresoli GL; Fiorino C; Rossa A; Bertini R; Colombo R; Da Pozzo L; Montorsi F; Roscigno M; Calandrino R; Rigatti P; Villa E
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):674-83. PubMed ID: 15183470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/ml undergoing radical prostatectomy for prostate cancer?
    Schumacher MC; Burkhard FC; Thalmann GN; Fleischmann A; Studer UE
    Eur Urol; 2006 Aug; 50(2):272-9. PubMed ID: 16632187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited.
    Vaidya A; Soloway MS
    J Urol; 2000 Dec; 164(6):1998-2001. PubMed ID: 11061900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
    Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
    J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens.
    Divrik RT; Eroglu A; Sahin A; Zorlu F; Ozen H
    Urol Oncol; 2007; 25(5):376-82. PubMed ID: 17826653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined radical prostatectomy and bladder augmentation for concomitant prostate cancer and detrusor instability.
    Quek ML; Barry P; Stein JP; Lieskovsky G; Ginsberg DA
    Urology; 2005 May; 65(5):964-7. PubMed ID: 15882732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen.
    Obek C; Louis P; Civantos F; Soloway MS
    J Urol; 1999 Feb; 161(2):494-8; discussion 498-9. PubMed ID: 9915434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
    Zincke H; Lau W; Bergstralh E; Blute ML
    J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. When is pelvic lymph node dissection necessary before radical prostatectomy? A decision analysis.
    Meng MV; Carroll PR
    J Urol; 2000 Oct; 164(4):1235-40. PubMed ID: 10992372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radical prostatectomy specimens among Medicare patients in New York State: a review of pathologists' reports.
    Imperato PJ; Waisman J; Nenner RP
    Arch Pathol Lab Med; 1998 Nov; 122(11):966-71. PubMed ID: 9822124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mycosis fungoides associated with B-cell malignancies.
    Barzilai A; Trau H; David M; Feinmesser M; Bergman R; Shpiro D; Schiby G; Rosenblatt K; Or R; Hodak E
    Br J Dermatol; 2006 Aug; 155(2):379-86. PubMed ID: 16882178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
    Shepard DR; Dreicer R; Garcia J; Elson P; Magi-Galluzzi C; Raghavan D; Stephenson AJ; Klein EA
    J Urol; 2009 Apr; 181(4):1672-7; discussion 1677. PubMed ID: 19230915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An unusual pathological finding of chronic lymphocitic leukemia and adenocarcinoma of the prostate after transurethral resection for complete urinary retention: case report.
    Ballario R; Beltrami P; Cavalleri S; Ruggera L; Zorzi MG; Artibani W
    BMC Cancer; 2004 Dec; 4():95. PubMed ID: 15615590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radical prostatectomy for clinical T4 prostate cancer.
    Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
    Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens.
    Maru N; Ohori M; Kattan MW; Scardino PT; Wheeler TM
    Hum Pathol; 2001 Aug; 32(8):828-33. PubMed ID: 11521227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens.
    Poulos CK; Daggy JK; Cheng L
    Cancer; 2004 Aug; 101(3):527-32. PubMed ID: 15274065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contemporary appraisal of radical perineal prostatectomy.
    Janoff DM; Parra RO
    J Urol; 2005 Jun; 173(6):1863-70. PubMed ID: 15879765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of minute adenocarcinomas of prostate at radical prostatectomy.
    Truskinovsky AM; Sanderson H; Epstein JI
    Urology; 2004 Oct; 64(4):733-7. PubMed ID: 15491711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.